Fosun Pharma and Jacobson have reached an agreement on the supply and distribution of the new crown vaccine for mRNA.

The main contents of the letter of intent 1, Fosun Industrial, Jacobson on the mRNA new crown vaccine in the cooperative area of the supply and distribution of cooperation reached an intention.
To supply Jacobson with 10 million doses of mRNA new crown vaccine to Jacobson based on the commercialization rights of the new crown vaccine in the cooperative region obtained by Fosun Industries on the basis of the re-licensing of the Fosun pharmaceutical industry, the terms of which are subject to further discussion.
2, the letter of intent will be terminated in the following circumstances (early) :(1) letter of intent signed 4 months after (2) Fosun Industrial written notice to Jacobson to terminate the letter of intent.
3. The letter of intent shall apply to the laws of the Hong Kong Special Administrative Region of China, and if the dispute cannot be resolved through negotiation under the letter of intent, it shall be submitted to the Hong Kong International Arbitration Centre for arbitration and shall be arbitrated in accordance with the arbitration rules in place at that time by the arbitration institution.
4, the letter of intent is the intention of the two sides to cooperate in the document, in addition to confidentiality, application of the law, dispute resolution and other provisions, the letter of intent for this cooperation did not create other binding rights and obligations.
5, the letter of intent from the two sides signed after the effective.
As of this announcement date, candidate vaccine products for the prevention of new coronavirus pneumonia based on mRNA technology are still in clinical stages in the United States, Germany and China, and no preventive vaccine based on mRNA technology platform has been approved worldwide. the
announcement indicates that the listing and sale of the mRNA new crown vaccine in the Hong Kong Special Administrative Region of China and the Macao Special Administrative Region of China requires the listing approval of the above-mentioned regional drug regulatory authorities, which depends on (including) other regulatory markets recognized in such regions regarding the approval of the vaccine on the market, etc., and that the approval of the vaccine for listing in such region is uncertain.
the partnership is based on uncertainty about whether the vaccine will be approved for listing in these regions.
.